NEW HAVEN, Conn. — November 18, 2025 — Leads & Copy — Invivyd, Inc. (IVVD) has announced the pricing of an underwritten public offering expected to generate approximately $125.0 million before deductions.
The offering consists of 44,000,000 shares of common stock priced at $2.50 per share and, for certain investors, pre-funded warrants to purchase 6,000,000 shares at $2.4999 per warrant. Invivyd has granted underwriters a 30-day option to purchase up to 7,500,000 additional shares at the public offering price, less underwriting discounts and commissions.
The offering is expected to close around November 19, 2025, contingent upon standard closing conditions.
Cantor is the sole book-running manager, and H.C. Wainwright & Co. is the lead manager for the offering.
Invivyd plans to use the net proceeds for commercial preparedness for a potential VYD2311 launch, research and development of pipeline programs like respiratory syncytial virus (RSV) and measles, advancement of the Spike Protein Elimination and Recovery (SPEAR) Study Group efforts related to assessing the effects of monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and for general corporate purposes.
The securities are offered under a shelf registration statement on Form S-3 (File No. 333-267643) filed with the SEC on September 28, 2022, and effective October 5, 2022.
The offering is made via a prospectus supplement and accompanying prospectus, available on the SEC’s website. Copies can be obtained from Cantor Fitzgerald & Co.
This announcement is neither an offer to sell nor a solicitation to buy securities, and there will be no sales in jurisdictions where such actions are unlawful prior to registration or qualification.
Invivyd is a biopharmaceutical company focused on protection from viral infectious diseases, starting with SARS-CoV-2. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb).
Media Relations
(781) 208-0160
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
Source: Invivyd, Inc.
